Investment Strategy

Consonance Capital Partners (“CCP”) looks to invest in U.S. lower to middle market companies that add sustainable value to the healthcare system by facilitating the delivery of higher quality care at a lower cost. The manager leverages its vast network and experience in the healthcare industry to proactively identify high growth industry subsectors, proven business models in emerging subsectors, and platform opportunities in unconsolidated subsectors. The team then systematically pursues opportunities within this framework that meet its core investment criteria.
Key to the process is the identification of world-class management teams who have a demonstrated ability to effectively navigate a highly complex and regulated industry. CCP deeply values these partnerships and believes that strong operators with aligned incentives are the backbone of a successful investment strategy.
Currently investing out of Consonance Private Equity II, L.P., an $856 million private equity fund, CCP targets growth equity, leveraged buyouts, and recapitalization transactions in the lower to middle market. Target companies generally have between $25 million and $500 million in revenues. The sources of these opportunities are typically derived from private/family-owned businesses seeking liquidity, growth capital, or both – and large corporations seeking to divest non-core assets. The principals build value for their investors by leveraging their relationships and resources to drive internal growth initiatives, operational improvements, and mergers & acquisitions.
With health care investing experience extending back over 30 years and across numerous economic cycles, the team has broad experience across multiple sub-sectors, including:

  • Providers (specialty providers, inpatient and outpatient facilities)
  • Payors (commercial, Medicare, Medicaid, and carve outs)
  • Distribution (pharmaceuticals, products, and specialty)
  • Devices (commercialized products)
  • Specialty pharmaceuticals (commercialized and later-stage development products)
  • Outsourced services (servicing managed care, pharma, and providers)
  • Healthcare information technology